Researched for 27 sec
Jun 23, 2025 1:28pm
Phase II PD‑(L)1 oncology assets with
no direct competitors in EU
Scanned sources in 87 languages
B2
Asset
Camrelizumab
Socazolimab
Company
Innovent
Junshi
Lead EU indic.
r/r nasopharyngeal
carcinoma
Cervical cancer
Next catalyst
ORR read‑out Q4 2025
PFS read‑out Q3 2025